MeSH term
Frequency | Condition_Probility | Blotting, Western | 3 | 0.0 |
Comparative Study | 28 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Humans | 217 | 0.0 |
Immunoenzyme Techniques | 32 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 28 | 0.0 |
Aged | 54 | 0.0 |
Aged, 80 and over | 17 | 0.0 |
Male | 88 | 0.0 |
Ligases/genetics | 2 | 5.0 |
Nerve Tissue Proteins/genetics | 3 | 1.0 |
Research Support, Non-U.S. Gov't | 101 | 0.0 |
Substantia Nigra/pathology | 2 | 20.0 |
*Ubiquitin-Protein Ligases | 3 | 0.0 |
Herpesvirus 4, Human/isolation & purification | 2 | 3.0 |
In Situ Hybridization | 6 | 0.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Adolescent | 21 | 0.0 |
Adult | 78 | 0.0 |
Child | 14 | 0.0 |
Child, Preschool | 11 | 0.0 |
Female | 80 | 0.0 |
Middle Aged | 69 | 0.0 |
Staining and Labeling/methods | 2 | 1.0 |
Animals | 21 | 0.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
Mutation | 3 | 0.0 |
Parkinson Disease/*genetics/pathology | 2 | 50.0 |
Cell Division | 4 | 0.0 |
DNA Primers | 2 | 0.0 |
Genotype | 6 | 0.0 |
Parkinson Disease/enzymology/*genetics | 2 | 20.0 |
Polymorphism, Genetic | 2 | 0.0 |
Reference Values | 4 | 0.0 |
Thiolester Hydrolases/*genetics | 3 | 21.0 |
Ubiquitin Thiolesterase | 6 | 5.0 |
Adenosinetriphosphatase/genetics | 2 | 4.0 |
Mice | 11 | 0.0 |
Molecular Sequence Data | 8 | 0.0 |
Autopsy | 3 | 1.0 |
DNA, Viral/analysis | 2 | 0.0 |
Immunohistochemistry | 59 | 0.0 |
Polymerase Chain Reaction | 5 | 0.0 |
Flow Cytometry | 11 | 0.0 |
Immunophenotyping | 20 | 0.0 |
*Mutation | 2 | 0.0 |
Leukocyte Count | 4 | 0.0 |
T-Lymphocytes/*pathology | 4 | 5.0 |
Disease Models, Animal | 2 | 0.0 |
Lymphoma, B-Cell/*pathology | 3 | 13.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Rats | 4 | 0.0 |
Transplantation, Heterologous | 2 | 0.0 |
Tumor Cells, Cultured | 5 | 0.0 |
Fatal Outcome | 3 | 0.0 |
Magnetic Resonance Imaging | 3 | 0.0 |
T-Lymphocytes/cytology | 2 | 2.0 |
Antigens, CD/analysis | 10 | 0.0 |
Antigens, CD20/analysis | 2 | 4.0 |
Antigens, CD4/analysis | 4 | 0.0 |
Antigens, CD45/analysis | 2 | 0.0 |
Antigens, CD8/analysis | 3 | 1.0 |
Antigens, CD/*analysis | 14 | 1.0 |
Dendritic Cells/*immunology | 2 | 0.0 |
Infant, Newborn | 5 | 0.0 |
Combined Modality Therapy | 4 | 0.0 |
Acute Disease | 2 | 0.0 |
English Abstract | 14 | 0.0 |
Antibodies, Monoclonal | 20 | 0.0 |
Cells, Cultured | 7 | 0.0 |
Skin Neoplasms/*pathology | 4 | 4.0 |
Biopsy | 16 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 4 | 2.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 11 | 3.0 |
Histocytochemistry | 3 | 0.0 |
Immunoglobulins, kappa-Chain/analysis | 2 | 9.0 |
Immunoglobulins, lambda-Chain/analysis | 2 | 12.0 |
Lymphoid Tissue/immunology/pathology | 2 | 25.0 |
Lymphoma, Non-Hodgkin/pathology | 3 | 21.0 |
Sensitivity and Specificity | 4 | 0.0 |
Tomography, X-Ray Computed | 5 | 0.0 |
Bone Marrow/pathology | 3 | 0.0 |
Lymph Nodes/pathology | 5 | 1.0 |
Microwaves | 2 | 8.0 |
Time Factors | 5 | 0.0 |
B-Lymphocytes/pathology | 8 | 9.0 |
Macrophages/pathology | 2 | 1.0 |
T-Lymphocytes/pathology | 8 | 7.0 |
Herpesvirus 4, Human/genetics/*isolation & purification | 2 | 11.0 |
RNA, Viral/*analysis | 2 | 3.0 |
B-Lymphocytes | 5 | 2.0 |
Microscopy, Electron | 5 | 0.0 |
T-Lymphocytes | 11 | 4.0 |
Antibodies, Monoclonal/immunology | 11 | 0.0 |
HLA-DR Antigens/analysis | 4 | 0.0 |
Lymphocyte Activation | 8 | 0.0 |
Lymphocytes/*immunology | 3 | 0.0 |
Monocytes/*immunology | 3 | 0.0 |
Phenotype | 24 | 0.0 |
Diagnosis, Differential | 13 | 0.0 |
Hodgkin Disease/*pathology | 2 | 16.0 |
Antibody Specificity | 3 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Logistic Models | 2 | 0.0 |
Cell Count | 3 | 0.0 |
Binding Sites, Antibody | 2 | 0.0 |
Mice, Inbred BALB C | 3 | 0.0 |
Antibodies, Monoclonal/diagnostic use | 15 | 1.0 |
Hodgkin Disease/*immunology/pathology | 2 | 12.0 |
Macrophages/immunology | 2 | 0.0 |
Paraffin Embedding | 9 | 3.0 |
T-Lymphocytes/immunology | 9 | 0.0 |
Tissue Fixation | 3 | 3.0 |
Tumor Markers, Biological | 2 | 0.0 |
Antigens, CD3/analysis | 3 | 1.0 |
Follow-Up Studies | 3 | 0.0 |
Lymphocytes/metabolism/*pathology | 2 | 28.0 |
Proto-Oncogene Proteins c-bcl-2 | 4 | 2.0 |
Base Sequence | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Carbimazole/therapeutic use | 2 | 33.0 |
Recurrence | 2 | 0.0 |
T-Lymphocytes/immunology/pathology | 4 | 6.0 |
Chronic Disease | 6 | 0.0 |
Pregnancy | 2 | 0.0 |
Lymphoma, B-Cell/*immunology | 2 | 5.0 |
Proto-Oncogene Proteins/analysis | 2 | 1.0 |
Bone Marrow/*pathology | 5 | 3.0 |
*Fixatives | 2 | 20.0 |
*Formaldehyde | 2 | 16.0 |
Histological Techniques | 6 | 12.0 |
Staining and Labeling | 12 | 1.0 |
Antibodies, Monoclonal/*immunology | 4 | 0.0 |
Phytohemagglutinins/immunology | 2 | 4.0 |
T-Lymphocyte Subsets/*immunology | 6 | 1.0 |
Skin/*pathology | 5 | 5.0 |
In Vitro | 6 | 0.0 |
*Lymphocyte Activation | 7 | 0.0 |
Retrospective Studies | 5 | 0.0 |
*Immunophenotyping | 2 | 1.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
Formaldehyde | 2 | 2.0 |
T-Lymphocytes/*immunology | 15 | 0.0 |
Age Factors | 7 | 0.0 |
Antigens, Differentiation/analysis | 9 | 2.0 |
Antigens, Neoplasm/*analysis | 9 | 2.0 |
Antigens, Viral/*analysis | 2 | 4.0 |
Infant | 7 | 0.0 |
Tumor Markers, Biological/*analysis | 4 | 0.0 |
Lymphoma, B-Cell/*immunology/*pathology | 2 | 40.0 |
Neoplasm Staging | 2 | 0.0 |
Amino Acid Sequence | 2 | 0.0 |
Fluorescent Antibody Technique | 8 | 0.0 |
B-Lymphocytes/*pathology | 2 | 4.0 |
Epithelium/immunology | 2 | 1.0 |
Antigens, CD45/*analysis | 4 | 8.0 |
Antigens, Neoplasm/analysis | 6 | 1.0 |
Antigens, Surface/analysis | 2 | 0.0 |
Leukemia, Myelocytic, Acute/*immunology/pathology | 2 | 20.0 |
Antigens, Differentiation, T-Lymphocyte | 5 | 1.0 |
Prognosis | 4 | 0.0 |
Reed-Sternberg Cells/*immunology/pathology | 2 | 40.0 |
Lymphoproliferative Disorders/pathology | 2 | 50.0 |
*Immunologic Memory | 8 | 5.0 |
Frozen Sections | 3 | 3.0 |
Immunohistochemistry/methods | 5 | 0.0 |
Receptors, Interleukin-2/analysis | 2 | 0.0 |
DNA Probes | 2 | 0.0 |
Gene Expression | 2 | 0.0 |
Kinetics | 3 | 0.0 |
Sialoglycoproteins/*analysis | 2 | 11.0 |
Epitopes | 2 | 0.0 |
Lymphoid Tissue/*immunology | 3 | 11.0 |
Paraffin | 7 | 15.0 |
Antigens, CD/*immunology | 3 | 0.0 |
Leukemia/immunology | 2 | 6.0 |
Lymphoma, B-Cell/immunology | 3 | 16.0 |
Antigens, Differentiation/*analysis | 5 | 2.0 |
Antigens, CD45 | 27 | 12.0 |
Cell Differentiation | 3 | 0.0 |
Histocompatibility Antigens/*analysis | 7 | 14.0 |
CD4-CD8 Ratio | 2 | 0.0 |
Membrane Glycoproteins/analysis | 6 | 2.0 |
Antibodies, Monoclonal/*diagnostic use | 12 | 5.0 |
Lymph Nodes/immunology | 3 | 3.0 |
Antigens, CD30 | 2 | 7.0 |
Antigens, CD3 | 5 | 1.0 |
Antigens, Differentiation, T-Lymphocyte/metabolism | 2 | 1.0 |
Receptors, Antigen, T-Cell/metabolism | 2 | 1.0 |
Lymphocytes/*pathology | 3 | 6.0 |
Skin Neoplasms/immunology/*pathology | 2 | 7.0 |
T-Lymphocytes, Helper-Inducer/immunology | 4 | 2.0 |
Receptors, Antigen, T-Cell/analysis | 2 | 1.0 |
Sex Factors | 3 | 0.0 |
Blotting, Southern | 3 | 0.0 |
Skin Neoplasms/*immunology | 2 | 5.0 |
Lymph Nodes/*pathology | 2 | 2.0 |
Antibodies, Monoclonal/analysis/*immunology | 2 | 16.0 |
Antigens, Differentiation/*immunology | 4 | 2.0 |
Cell Line | 5 | 0.0 |
Histocompatibility Antigens/*immunology | 2 | 8.0 |
Molecular Weight | 6 | 0.0 |
Transfection | 2 | 0.0 |
Skin Neoplasms/*diagnosis/immunology | 2 | 33.0 |
Hodgkin Disease/pathology | 2 | 20.0 |
Lymphoid Tissue/pathology | 2 | 22.0 |
B-Lymphocytes/*immunology | 3 | 0.0 |
Hodgkin Disease/immunology | 2 | 18.0 |
Lymphoma/*immunology | 2 | 6.0 |
Spleen/immunology | 2 | 1.0 |
Thymus Gland/immunology | 2 | 3.0 |
Histocompatibility Antigens/analysis | 6 | 9.0 |
Phytohemagglutinins/pharmacology | 2 | 0.0 |
Receptors, Antigen, T-Cell/*analysis | 3 | 5.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis | 3 | 1.0 |
Lymphoma, T-Cell/*diagnosis/immunology | 2 | 100.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Antigens, CD/*biosynthesis | 2 | 1.0 |
Antigens, Differentiation/*biosynthesis | 2 | 6.0 |
CD4-Positive T-Lymphocytes/*immunology | 2 | 0.0 |
Histocompatibility Antigens/*biosynthesis | 2 | 66.0 |
CA-15-3 Antigen | 2 | 2.0 |
Survival Rate | 2 | 0.0 |
Freezing | 3 | 3.0 |
Paraffin/diagnostic use | 2 | 100.0 |
Immunoglobulins/analysis | 2 | 0.0 |
Antigens, CD8 | 6 | 2.0 |
CD4-Positive T-Lymphocytes/immunology | 3 | 0.0 |
Lymphoma, Non-Hodgkin/*pathology | 3 | 21.0 |
Lymphocytes/pathology | 3 | 3.0 |
Lymphocyte Activation/*immunology | 2 | 0.0 |
Lymphoma/immunology | 2 | 6.0 |
Tonsil/cytology | 2 | 2.0 |
Antigens, Differentiation, T-Lymphocyte/*immunology | 2 | 0.0 |
Antigens/*immunology | 2 | 2.0 |
Receptors, Antigen, T-Cell, alpha-beta | 2 | 5.0 |
Cell Separation | 4 | 0.0 |
Antigens, Differentiation/immunology | 3 | 2.0 |
B-Lymphocytes/immunology | 4 | 0.0 |
Hematologic Diseases/*pathology | 2 | 40.0 |
Leukemia/pathology | 2 | 6.0 |
Fixatives | 2 | 2.0 |
Skin Diseases/*pathology | 2 | 8.0 |
Lymphocyte Culture Test, Mixed | 3 | 0.0 |
Cross Reactions | 2 | 0.0 |
Parkinson Disease/*genetics | 2 | 2.0 |
Ubiquitin-Protein Ligases/genetics | 2 | 10.0 |
Lymphoma/*diagnosis | 2 | 40.0 |
B-Lymphocytes/immunology/pathology | 2 | 4.0 |
Lymphoma, Non-Hodgkin/analysis/*pathology | 2 | 100.0 |
Antigens, Surface/*analysis | 2 | 1.0 |
Lymphoma/pathology | 2 | 7.0 |
T-Lymphocytes/*classification | 2 | 5.0 |
Tonsil/immunology | 3 | 4.0 |
Lymphocyte Function-Associated Antigen-1 | 2 | 2.0 |
T-Lymphocytes/classification/cytology/*immunology | 2 | 25.0 |
Lymphocytes/*classification | 2 | 11.0 |
Antigens, CD2 | 2 | 0.0 |
Histocompatibility Antigens/immunology | 3 | 17.0 |
Epitopes/*analysis | 4 | 2.0 |
Epithelial Cells | 2 | 0.0 |
Antigen-Antibody Reactions | 5 | 1.0 |
T-Lymphocytes/*classification/immunology | 3 | 10.0 |
T-Lymphocytes, Helper-Inducer/*classification | 2 | 50.0 |
Antigens/*analysis | 2 | 2.0 |
Interferon Type II/*biosynthesis | 2 | 1.0 |
T-Lymphocytes, Suppressor-Effector/immunology | 2 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Antigens, Differentiation/*analysis/immunology | 2 | 18.0 |
